D-0020-2023 Class II Terminated
FDA drug recall D-0020-2023 was initiated by AuroMedics Pharma LLC on Sep 30, 2022 and is designated Class II. Reason for recall: Subpotent Drug: Out of specification for assay The recall status is terminated (terminated Sep 18, 2024). Affected quantity: 11,520 units.
Recall Details
- Product Type
- Drugs
- Report Date
- Nov 2, 2022
- Initiation Date
- Sep 30, 2022
- Termination Date
- Sep 18, 2024
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 11,520 units
Product Description
Fondaparinux Sodium Injection, USP, 7.5 mg per 0.6 mL, Single Dose, Prefilled Syringe, Distributed by: AuroMedics Pharma LLC 279 Princeton-Hightstown Rd. E. Windsor, NJ 08520. Made in India. NDC 55150-232-10 (carton)NDC 55150-232-00 (syringe)
Reason for Recall
Subpotent Drug: Out of specification for assay
Distribution Pattern
Nationwide in the USA
Code Information
Lot # CFN200020, EXP Nov. 2022
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-0020-2023
- openFDA file date
- Nov 3, 2026
- Loaded by RegDataLab
- Nov 4, 2026